Cargando…

NFB-04. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on PBTC-029B

BACKGROUND: Focal Areas of Signal Intensity (FASI) are T2 hyperintense benign lesions in children with NF1. They can mimic the appearance of low-grade glioma (LGG). Selumetinib has shown efficacy in treatment of NF1-associated LGG but treatment effects on FASI have not yet been described. METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pillay Smiley, Natasha, Leach, James, Lane, Adam, Hummel, Trent, Fangusaro, Jason, de Blank, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Neurofibromatosis and other Predisposition Syndromes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165296/ http://dx.doi.org/10.1093/neuonc/noac079.468

Ejemplares similares

Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B
por: Pillay-Smiley, Natasha, et al.
Publicado: (2023)

NFB-15. "Cognitive Impairments in Children and Adolescents with Neurofibromatosis"
por: Mavrea, Kalliopi, et al.
Publicado: (2022)

NFB-21. Neurofibromatosis Type I in the Setting of Neuro-Oncology
por: Hemenway, Molly
Publicado: (2022)

NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1)
por: Roka, Kleoniki, et al.
Publicado: (2022)

NFB-03. Neurological manifestations in children and adolescents with Neurofibromatosis type 1 - Implications for management and surveillance
por: Angelova-Toshkina, Daniela, et al.
Publicado: (2022)

NFB-08. TRAM-01: A Phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
por: Kiaei, Dorsa Sadat, et al.
Publicado: (2022)

NFB-07. Meningiomatosis in an adolescent with TRAF-7 mutation related syndrome
por: Torres, Marleni, et al.
Publicado: (2022)

NFB-20. Pre-clinical models of Mismatch Repair Deficient Gliomas
por: Putnam, Ethan, et al.
Publicado: (2022)

NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies
por: Marks, Asher, et al.
Publicado: (2022)

NFB-09. Treatment of cardiac fibroma in aPTCH1-mutated Gorlin syndrome with medulloblastoma
por: Piccolo, Gianluca, et al.
Publicado: (2022)

NFB-06. Laser Interstitial Thermal Therapy as a Radiation-Sparing Approach for Children with Cancer Predisposition
por: Guadix, Sergio, et al.
Publicado: (2022)

NFB-12. Effect of trametinib on leg length discrepancy in a child with NF1 related plexiform neurofibroma
por: Pradeep, Celia, et al.
Publicado: (2022)

NFB-23. Extent of tumor but not location may be predictive of longitudinal disease severity in children with NF1-associated gliomas requiring treatment
por: Chaturvedi, Sneha, et al.
Publicado: (2022)

NFB-02. Maternal high-fat diet exposure increases the proliferation and glial differentiation of the cells of origin for NF1-optic glioma
por: Zhang, Kailong, et al.
Publicado: (2022)

NFB-01. Central nervous system tumors in Von Hippel-Lindau multisystem disorder: are there preventive approaches to escape tumor initiation at a young age?
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2022)

NFB-14. PSYCHOSOCIAL OUTCOMES IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS
por: Damodharan, Sudarshawn, et al.
Publicado: (2020)

NFB-04. EXAMINING DIFFUSION, ARTERIAL SPIN-LABELED PERFUSION, AND VOLUMETRIC CHANGES IN THE NEUROFIBROMATOSIS TYPE 1 BRAIN USING AN ATLAS-BASED, MULTI-PARAMETRIC APPROACH
por: Tam, Lydia, et al.
Publicado: (2020)

NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS
por: Phadnis, Sheetal, et al.
Publicado: (2020)

NFB-05. AN UNUSUAL PRESENTATION OF RECURRENT LANGERHANS CELL HISTIOCYTOSIS OF THE CRANIOFACIAL BONES IN A PATIENT WITH NEUROFIBROMATOSIS TYPE I
por: Chaffee, Blake, et al.
Publicado: (2020)

NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY
por: Fisher, Michael J, et al.
Publicado: (2020)

NFB-18. IMMUNE FUNCTION IN CHILDREN TREATED WITH TRAMETINIB
por: Moukhaiber, Perla, et al.
Publicado: (2020)

NFB-02. TREATMENT OF PAIN AND TUMOR GROWTH IN NF2
por: Hemenway, Molly, et al.
Publicado: (2020)

NFB-13. TRAMETINIB FOR PLEXIFORM NEUROFIBROMA AND RECURRENT LOW-GRADE GLIOMA
por: Sato, Aimee, et al.
Publicado: (2020)

NFB-03. TRAMETINIB FOR ORBITAL PLEXIFORM NEUROFIBROMAS IN YOUNG CHILDREN WITH NF1
por: Toledano, Helen, et al.
Publicado: (2020)

NFB-11. WHITE MATTER DIFFERENCES IN CHILDREN WITH NF1 COMPARED TO CONTROLS
por: Bruckert, Lisa, et al.
Publicado: (2020)

NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM
por: Mueller, Sabine, et al.
Publicado: (2020)

NFB-01. FUNCTIONAL CHARACTERIZATION OF ATRX LOSS IN NF1-ASSOCIATED GLIOMA AND MPNST
por: Yuan, Ming, et al.
Publicado: (2020)

NFB-12. TRAMETINIB THERAPY FOR PEDIATRIC PATIENTS WITH REFRACTORY LOW GRADE GLIOMA OR EXTENSIVE SYMPTOMATIC PLEXIFORM NEUROFIBROMA
por: Hounjet, Celine D, et al.
Publicado: (2020)

NFB-07. USE OF PEGYLATED INTERFERON α- 2b IN PEDIATRIC PATIENTS AFFECTED BY UNRESECTABLE PLEXIFORM NEUROFIBROMAS: MONOCENTRIC EXPERIENCE
por: Cacchione, Antonella, et al.
Publicado: (2020)

NFB-16. mTOROPATHIES AND SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: PREDICTIVE VALUE OF GERMINAL TSC1/2 MUTATIONS SCREENING IN FAMILIAL CASES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2020)

NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES
por: Baig, Muhammed, et al.
Publicado: (2020)

LGG-04. A PHASE II RE-TREATMENT STUDY OF SELUMETINIB FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (pLGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
por: Fangusaro, Jason, et al.
Publicado: (2020)

LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial
por: Fangusaro, Jason, et al.
Publicado: (2022)

MRI Screening for Optic Gliomas in Neurofibromatosis Type 1
por: Millichap, J. Gordon
Publicado: (2015)

Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
por: Patel, YT, et al.
Publicado: (2017)

Fasys: Visible-Light-Based Communication and Positioning Services towards Smart Cities
por: Yu, Baozhu, et al.
Publicado: (2023)

Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
por: Tian, Zhuowei, et al.
Publicado: (2023)

Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma
por: Blackwood, Nigel, et al.
Publicado: (2023)

Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo
por: Osum, Sara H, et al.
Publicado: (2021)

EPCT-02. PBTC-051: FIRST IN PEDIATRICS PHASE 1 STUDY OF CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M IN PEDIATRIC SUBJECTS WITH RECURRENT/REFRACTORY BRAIN TUMORS
por: Lindsay, Holly, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cppivtdcurt689t2pft3pjp5um